Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease.

This research and development focus offers tremendous potential to identify novel, high-value therapies addressing a wide range of diseases and disorders triggered by inflammation, including asthma and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Amira’s research strategy emphasizes systematic and early evaluation of compounds’ pharmacokinetics, pharmacodynamics and safety, leading to definitive “go-no go” decisions. The efficiency of this research process is enhanced by the discovery team’s unparalleled insights into the eicosanoid pathway, a complex signaling process that exerts control over inflammation.

Amira’s founders were pivotal in the discovery of several high-profile and successful clinical compounds, including Arcoxia^®, Singulair ^® and Vioxx ^®. This track record, combined with Amira’s focus on identifying high-value compounds within the eicosanoid pathway, has enabled Amira to generate $40 million in funding from its investors and to discover four highly-targeted, novel compounds, all within two years of the company’s 2005 founding.